Global Catastrophe Or Passing Nuisance? Pharma’s Coronavirus Views
Quarterly Briefings Focus On Continuity
While the global health threat from the now officially named SARS-CoV-2 coronavirus has grown since the start of the quarterly earnings season in early February, even many of the companies reporting more recently do not appear overly concerned about potential business impact at this stage.
